ADRX ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.…
Industry Peers
BiotechnologyKey Statistics
About ADARx Pharmaceuticals (NASDAQ: ADRX)
›
ADARx Pharmaceuticals (NASDAQ: ADRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 100 employees.
The shares were at 14.20 USD on 13 November 2026. Its 52-week range is 12.50 USD to 23.21 USD: the price is 38.8% below the high and 13.6% above the low.
Its market capitalisation is 1.57B USD.
ADARx Pharmaceuticals reports return on equity of 36.1% and revenue up 258.7% year over year.
It holds more cash than debt, a net cash position of 420.35M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 4 analysts cover the stock; their mean price target of 34.25 USD is 141.2% above the current price.